2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-100312
    (±)-WS75624B 188048-45-5 98%
    (±)-WS75624B is an endothelin converting enzyme (ECE) inhibitor with an IC50 of 0.03 μg/mL.
    (±)-WS75624B
  • HY-100322
    H100 643727-55-3 99.17%
    H100 is a Cl- transport inhibitor, with partial effects against both the NaK2Cl cotransporter and the Band 3 anion exchanger, but no effect against KCl cotransporter, in human erythrocytes.
    H100
  • HY-100607
    Landiolol 133242-30-5 98%
    Landiolol (ONO1101) is a highly selective, ultra-short-acting competitive inhibitor of β1 adrenergic receptors. Landiolol specifically blocks cardiac β1 receptors, reducing heart rate and myocardial oxygen consumption. Landiolol inhibits TNF-α-induced excessive mitochondrial oxygen consumption and reactive oxygen species production in a sepsis model, alleviating renal injury. Landiolol has little effect on cardiac ion channels (such as L-type calcium current and inward rectifier potassium current) and has a weak negative inotropic effect. Landiolol can be used for perioperative tachycardia control and protection studies of sepsis-related acute kidney injury.
    Landiolol
  • HY-100623
    Dofetilide N-oxide 144449-71-8 98%
    Dofetilide N-oxide (UK-116856) is a metabolite of Dofetilide. Dofetilide is a class III antiarrhythmic agent that blocks potassium channels.
    Dofetilide N-oxide
  • HY-100795
    Pirmenol 68252-19-7 99.32%
    Pirmenol is an orally active antiarrhythmic agent. Pirmenol inhibits IK.ACh (IC50: 0.1 μM) by blocking mAchR. Pirmenol can be used in the research of cardiovascular disease, such as atrial fibrillation.
    Pirmenol
  • HY-100851
    LY-272015 159730-07-1 98%
    LY-272015 is an orally active, specific 5-HT2B receptor antagonist. LY-272015 completely inhibits the phosphorylation of ERK2 induced by 5-HT or BW723C86. LY-272015 is antihypertensive in Deoxycorticosterone Acetate (DOCA)-salt-hypertensive rats.
    LY-272015
  • HY-101008
    3-MPPI 133399-65-2 98%
    3-MPPI is a GPCR ligand with high selectivity for α1-adrenergic receptor, with a Ki value of 0.21 nM for α1-adrenergic receptor and 50 nM for 5-HT1A receptor. 3-MPPI modulates the α1-adrenergic receptor signaling cascade. 3-MPPI is applicable to research related to hypertension, stress-induced anxiety-like behavioral responses, and levodopa-induced dyskinesia.
    3-MPPI
  • HY-101045
    AT-112 139047-55-5 98%
    AT-112 is a ketotanserin analogue. AT-112 has hemodynamic effects. AT-112 significantly reduces portal vein branch blood flow and portal vein pressure. AT-112 can be used to study the pathogenesis of portal hypertension.
    AT-112
  • HY-101050
    Tropanserin 85181-40-4 99.92%
    Tropanserin is a serotoninergic active compound, as well as a 5HT3 receptor antagonist. Tropanserin modulates Cardio-respiratory reflex effects of an exogenous serotonin challenge.
    Tropanserin
  • HY-101061
    2-MPMDQ 149847-77-8 98%
    2-MPMDQ is a potent and selective α1-adrenoceptor (Ki=0.37 nM) antagonist over α2-adrenoceptor (Ki=1740 nM). 2-MPMDQ is potent anti-hypertensive agent and has the potential for hypertension research.
    2-MPMDQ
  • HY-10119S
    Vorapaxar-d5 98%
    Vorapaxar-d5 is deuterated labeled Vorapaxar (HY-10119). Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner.
    Vorapaxar-d5
  • HY-101235
    ICI 185282 106393-80-0 98%
    ICI 185282 is a potent, selective, orally active thromboxane A2 (TXA₂) receptor antagonist. ICI 185282 causes dose-dependent inhibition of U-46619 (HY-108566)-induced platelet aggregation ex-vivo in guinea-pig. ICI 185,282 inhibits bronchospasm induced by U-46619, PGD2 (HY-101988), PGF2α (HY-12956), arachidonic acid (HY-109590), LTD4 and PAF (HY-108635) in vivo. ICI 185282 can be used for bronchial asthma research.
    ICI 185282
  • HY-101304
    S-Isopropylisothiourea hydrobromide 4269-97-0 98.0%
    S-Isopropylisothiourea hydrobromide (S-isopropyl ITU; IPTU) is a blood-brain barrier (BBB) penetrant NOS inhibitor with IC50 values of 0.66, 0.75 and 0.29 μM against mouse spinal cord, cerebellar, bovine aortic and porcine endothelial cell NOS. S-Isopropylisothiourea exhibits a significant blood pressure-raising effect without damaging the perfusion of vital organs and can also inhibit the late-phase pain response induced by formalin. S-Isopropylisothiourea hydrobromide is used in the researchs for hemorrhagic shock and pain response based on NOS.
    S-Isopropylisothiourea hydrobromide
  • HY-101345
    AH 11110A 179388-65-9 98%
    AH 11110A is an α1B-adrenoceptor antagonist, but it can't effectively distinguish between the different subtypes of alpha(1) adrenoceptors (A, B, and D), nor can it clearly differentiate between alpha(1) and alpha(2) adrenoceptors.
    AH 11110A
  • HY-101355
    CGP 20712 137888-49-4 98%
    CGP 20712 is a highly selective β1-adrenoceptor antagonist (Ki=0.3 nmol/L). CGP 20712’s primary mechanism of action is through competitively binding to β1-receptors, thereby blocking the positive chronotropic effects of adrenaline and noradrenaline.
    CGP 20712
  • HY-101374
    AGN 192403 175521-95-6 98%
    AGN 192403 (BRD4780) is a potent and selective imidazoline-1 receptor antagonist with a Ki value of 42 nM. AGN 192403 is also a TMED9 inhibitor. AGN 192403 shows protective effects on oxidative cytotoxicity and mitochondrial inhibitor-induced cytotoxicity in astrocytes. AGN 192403 mitigates the proliferation and migration of differentiated glioma tumor cells. AGN 192403 can be used for glioma tumor and neurological diseases research.
    AGN 192403
  • HY-101393
    CGP 12177 81047-99-6 98%
    CGP 12177 ((±)-CGP 12177) is a β-Adrenergic receptor (β-AR) ligand. CGP 12177 is a β3-AR (Ki = 88 nM) agonist with β1/β2-AR (Ki = 0.9 nM for β1; Ki = 4 nM for β2) antagonist action. CGP 12177 exhibits partial agonist properties for α1-AR in rat pulmonary artery. CGP 12177 regulates the expression of ucp and leptin genes in NMRI mice adipose tissues. CGP 12177 can be used for cardiovascular and metabolic disease research.
    CGP 12177
  • HY-101433
    N-Acetylprocainamide hydrochloride 34118-92-8 99.83%
    N-Acetylprocainamide (Acecainide) hydrochloride is a class III antiarrhythmic, which blocks K+ channels. N-Acetylprocainamide hydrochloride exerts inhibitory effects on the maximum following frequency (MFF) of isolated rabbit atria. N-Acetylprocainamide hydrochloride can be used for the study of arrhythmias.
    N-Acetylprocainamide hydrochloride
  • HY-101436
    Sematilide 101526-83-4 98%
    Sematilide (CK-1752) is a selective IKr channel blocker. Sematilide causes a concentration-dependent inhibition of the delayed rectifier K+ current (IC50=25 μM). Sematilide is a class III antiarrhythmic agent.
    Sematilide
  • HY-101542
    Milfasartan 148564-47-0 98%
    Milfasartan (LR-B/081) is a selective angiotensin receptor AT1 antagonist with antihypertensive activity.
    Milfasartan
Cat. No. Product Name / Synonyms Application Reactivity